HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 19 March 2015

Ledipasvir-sofosbuvir for treating chronic hepatitis C

In draft guidance, NICE has recommended ledipasvir-sofosbuvir (Harvoni, Gilead Sciences) as a treatment option for some adults with genotype 1 or 4 chronic hepatitis C.  It is not recommended (in combination with ribavirin) for treatment of GT3.

There have been lots of Hep C appraisals in the last couple of years; boceprevir, telaprevir, simeprevir, sofosbuvir.  An interesting difference with this appraisal is with the potential use of alternative treatment durations recommended by the EMA.  The use of these alternative durations has a substantial impact upon the cost-effectiveness of LDV/SOF; shortened treatment durations were a lot more cost-effective.

The ERG report was produced by SHARR-TAG, with the HEDS authors being Praveen Thokala, Emma Simpson, Paul Tappenden, John Stevens and Kath Dickinson.